Debt-to-equity of Virpax Pharmaceuticals, Inc. from 30 Sep 2021 to 31 Dec 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Virpax Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 31 Dec 2024.
  • Virpax Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 31 Dec 2024 was -209%, a 454% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Virpax Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2024 -209% -268% -454% 31 Dec 2024
Q3 2024 -479% -512% -1564% 30 Sep 2024
Q2 2024 540% +518% +2310% 30 Jun 2024
Q1 2024 114% +97% +579% 31 Mar 2024
Q4 2023 59% +46% +370% 31 Dec 2023
Q3 2023 33% +23% +248% 30 Sep 2023
Q2 2023 22% +16% +262% 30 Jun 2023
Q1 2023 17% +8.4% +100% 31 Mar 2023
Q4 2022 13% +0.66% +5.6% 31 Dec 2022
Q3 2022 9.4% -16% -63% 30 Sep 2022
Q2 2022 6.2% 30 Jun 2022
Q1 2022 8.4% 31 Mar 2022
Q4 2021 12% 31 Dec 2021
Q3 2021 26% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.